Hypothyroidism describes an ineffective thyroid gland that cannot make enough thyroid hormone. This condition has no cure and can only be controlled by replacing the hormone with a thyroid gland. The signs and symptoms of hypothyroidism are fatigue, constipation, dry skin, puffy face, muscle weakness, muscle aches, tenderness, stiffness, pain and stiffness. The major risk factors affecting by hypothyroidism are autoimmune diseases, thyroid surgery, radiation therapy and family history of thyroid disease.
According to the study “Hypothyroidism – Pipeline Review, H1 2018”, on a global scale the population with iodine deficiency is increasing drastically. Iodine deficiency is predominant compared to the large consumers of iodine and is particularly observed in pregnant women and young children. Human body consists of minute amounts of iodine in the thyroid gland and plays a major role in thyroid synthesis. Research reports state that over two billion global populations have insufficient iodine intake. The introduction of various remedies for the treatment of thyroid deficiency has encouraged the thyroid therapeutics market over the past few years. It was observed that there is a growing demand for the thyroid therapeutics in the developed and developing regions worldwide. Therefore, thyroid therapeutic vendors are focusing more on the emerging economies such as the Middle East, Africa, China, and India. According to the research reports about 42 million people in India suffer from hypothyroidism.
The global thyroid therapeutics market is largely dominated by three leading vendors; AbbVie, Pfizer, and Merck Sharp & Dohme. These vendors account for a major part of the revenue shares. Abbvie invests in discovery, development, manufacturing, and marketing the thyroid pharmaceutical products. Other leading competitors in thyroid therapeutics market are Abbott, Allergan and RLC LABS. Geographically, more American population account for hypothyroidism and opt for thyroid gland disorder treatments. Globally, the population with hypothyroidism is expected to increase the next few years due to modernisation and increase in lifestyle diseases.
The pipeline review guide for hypothyroidism provides comprehensive analysis on the therapeutics that are under development, various drug analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type involved in hypothyroidism therapeutics. It also covers a descriptive pharmacological action of the therapeutics, complete research and development history and latest news and press reports related to hypothyroidism. The guide also provides details related to key players involved in therapeutic development for Hypothyroidism, information related to emerging players, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The hypothyroidism guide is generated using information from various sources and dynamic tracking processes that provide most recent developments are captured on a real time basis. This trend will continue over the next few years so as to provide best treatment for the increasing population with hypothyroidism.
To know more, click on the link below:
Ankur Gupta, Head Marketing & Communications